Scopus h-index:10
- Home
- Profiles
Brian D Radbill, MD
Internal Medicine, Nephrology
No Patient Experience Ratings
- About Me
- Clinical Focus
- Education & Certifications
- Research
- Insurance
- Publications
- Industry Relationships
About Me
In the News
Dr. Radbill discusses chronic kidney disease in The Daily News feature The Daily Check Up.
View the PDF.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
In the News
Dr. Radbill discusses chronic kidney disease in The Daily News feature The Daily Check Up.
View the PDF.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
In the News
Dr. Radbill discusses chronic kidney disease in The Daily News feature The Daily Check Up.
View the PDF.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
Clinical Focus
- Chronic Renal Failure
- Dialysis
- Glomerulonephritis
- Hematuria
- High Blood Pressure
- Hypertension (High Blood Pressure)
- Kidney Biopsy
- Kidney Failure
- Kidney Stones
Show More
- Chronic Renal Failure
- Dialysis
- Glomerulonephritis
- Hematuria
- High Blood Pressure
- Hypertension (High Blood Pressure)
- Kidney Biopsy
- Kidney Failure
- Kidney Stones
- Nephrotic Syndrome
- Renovascular Hypertension
Education
BA, University of Michigan
MD, Hahnemann University School of Medicine
MD, Hahnemann University
, Mount Sinai School of Medicine
, Mount Sinai School of Medicine
Internship, Internal Medicine
The Mount Sinai Hospital
Residency, Nephrology
The Mount Sinai Hospital
Fellowship, Nephrology
The Mount Sinai Hospital
Certifications
Nephrology
American Board of Internal Medicine
Research
Renal interstitial fibrosis (RIF) is the end result of chronic kidney disease (CKD) and is predictive of long-term renal survival and its inhibition might delay progression towards end-stage renal disease (ESRD). Since type IV collagen-rich extracellular matrix is replaced by type-1 collagen after injury, the hypothesis is being tested that matrix metalloproteinase-2 (MMP-2), a type IV collagenase, may play a causative role in renal fibrosis. Mechanistic studies are underway using an MMP-2 -/- mouse to determine whether MMP-2 promotes renal tubular epithelial-mesenchymal transition (EMT), myofibroblast proliferation and fibrogenesis with and without unilateral ureteral obstruction (UUO), a murine model of RIF.
In addition, the role of MMP-2 in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) is under study comparing MMP-2 and fibrognesis marker gene and protein expression by human ADPKD epithelia versus normal renal tubular cell lines in vitro.
Insurance Information
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Article:10
Review Article:2
Comment/Debate:1
Chapter:1
Recent Artifacts
- The Impact of Bedside Interdisciplinary Rounds on Length of Stay and Complications
- Data-driven identification of risk factors of patient satisfaction at a large urban academic medical center
- Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients
- The surgical management of renal hyperparathyroidism
- Diabetic kidney disease in the elderly
- Clinical and molecular epidemiology of methicillin-resistant staphylococcus aureus among patients in an ambulatory hemodialysis center
- Diagnosis, treatment goals, and Management of diabetic kidney disease in the elderly
- Erratum
- Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen i expression
- Retained Catheter Fragment from a Fractured Tunneled Catheter-A Rare and Potentially Lethal Complication
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Radbill during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- New York College of Podiatric Medicine (NYCPM)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.